Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 111.36 -1.43 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $112.79 | 52 Week High | $118.49 | |||
| Open | $114.05 | 52 Week Low | $55.00 | |||
| Day High | $114.05 | P/E | N/A | |||
| Day Low | $111.26 | EPS | $-0.56 | |||
| Volume | 1,478,547 | |||||
